Indonesia Pharmaceuticals and Healthcare Report Q2 2009

Publication Date	April 2009
Publisher	Business Monitor
Product Type	Report
Pages	93
ISBN Number	not applicable
Product Code	BMI03635

Buy this product or for assistance call +44 20 7060 7474

PDF £250.00$410 | €277

FAX Order above formats by FAX

Summary

Indonesia is one of the most promising long-term opportunities for pharmaceutical companies. However, numerous short-term challenges must be overcome, such as protectionist government and inequitable access to healthcare. The value of pharmaceuticals sold in 2008 reached US$2.79bn and BMI is forecasting a compound annual growth rate (CAGR) of 11.85% through 2013.

In February 2009 it was revealed that the Indonesian government would give IDR300bn (US$24.7mn) to local drugmakers who had been hard hit by the volatile prices of raw materials and intense pressure from rivals operating from low-cost bases. In return for the subsidy and an accelerated registration process, pharmaceutical companies must produce more affordable generic drugs. Health Minister Siti Fadilah Supari said, 'The programme will enable the national pharmaceutical industry to deal with the crisis.' This development was the first time a government had bailed out its pharmaceutical industry in the midst of the global financial downturn.

Highlighting it status as a leading Muslim nation, Indonesia announced in December 2008 that it would increase the value of medicine donations to Palestinians in Gaza from IDR2bn (US$167,000) to IDR10bn (US$835,000). The government said it would send domestically-manufactured medicines with a value of IDR300mn (US$25,000) and distribute IDR10bn to purchase more drugs in Egypt. This gesture is highly significant because Indonesia is struggling to provide its own citizens with affordable pharmaceuticals.

Despite being a highly religious country, 'morning after' pills are freely available in certain parts of Indonesia without a prescription. The Food and Drugs Monitoring and Counselling Team (TP2MO) were instructed in February 2009 to monitor the sales of the pills, which retail for IDR200,000 (US$16.73).

However, given that TP2MO only carry out monitoring twice a year, an effective crackdown is unlikely in the short term.

Healthcare sector reform is underway, but challenges are numerous. In December 2008, it was revealed that some hospitals - both private and public - had been caught refusing treatment to patients on low incomes or those using the Public Health Assurance Programme (Jamkesmas). Those that restrict service will face 'sanctions'. All hospital care in the Indonesia is free of charge for low-income families.

However, patients must sign up for the public health insurance program in their locality.

Content

Executive Summary
Indonesia Pharmaceutical And Healthcare Industry SWOT
Indonesia Political SWOT
Indonesia Economic SWOT
Indonesia Business Environment SWOT
Pharmaceutical Business Environment Ranking
Limits Of Potential Returns
Risks To Realisation Of Returns
Indonesia - Market
Regulatory Regime
Intellectual Property Issues
Generic Drug Legislation
Labelling Requirements
Counterfeit And Substandard Drugs
Free Trade Agreements
Pricing Regime
Reimbursement Regime
Price Cuts
Industry Trends And Developments
Epidemiology
Avian Flu
International Avian Flu Partnerships
Healthcare System
Healthcare System Reform
International Healthcare Collaborations
Pharmaceutical Sector
Recent Pharmaceutical Industry Developments
Pharmaceutical Retail Sector
Research And Development
Herbal Medicines
Medical Devices
Industry Forecast Scenario
Overall Market Forecast
Key Growth Factors - Industry
Key Growth Factors - Macroeconomic
Prescription Market Forecasts
Patented Market Forecast
Generics Market Forecast
OTC Market Forecast
Export/Import Forecast
Medical Devices Market Forecast
Other Healthcare Data And Forecasts
Key Risks To BMI's Forecast Scenario
Competitive Landscape
Company Profiles
Leading Foreign Manufacturers
Sanofi-Aventis
Pfizer
Novartis
GlaxoSmithKline
Merck & Co
Bayer
Indigenous Manufacturers
PT Kalbe Farma
PT Bio Farma
Kimia Pharma
PT SidoMuncul
Combiphar PT
Darya-Varia
Country Snapshot: Indonesia Demographic Data
Section 1: Population
Section 2: Education And Healthcare
Section 3: Labour Market And Spending Power
BMI Forecast Modelling
How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceutical Business Environment Ratings Methodology
Ratings Overview
Weighting
Sources
List of Tables
- Table: Asia Pacific Pharmaceutical Business Environment Ratings For Q209
- Table: UN Millennium Development Goals
- Table: Indonesia - Medical Device Market Forecast
- Table: Indonesia - Drug Expenditure Indicators, 2003-20
- Table: Indonesia - Health Expenditure Indicators, 2003-2013
- Table: Indonesia - Economic Activity
- Table: Indonesia - Prescription Market Indicators, 2003-2013 (IDRmn unless otherwise stated)
- Table: Indonesia - Patented Drug Market Indicators, 2003-2013
- Table: Indonesia - Generic Drug Market, 2003-2013 (IDRmn unless otherwise stated)
- Table: Indonesia - OTC Drug Market, 2003-2013
- Table: Indonesia - Pharmaceutical Trade Indicators, 2003-2013 (US$mn)
- Table: Indonesia - Medical Device Market Indicators, 2004-2013 (US$mn unless otherwise stated)
- Table: Indonesia - Other Health Indicators, 2003-2013
- Table: Indonesia's Pharmaceutical Market Landscape (Q406)
- Table: Demographic Indicators, 2005-2030
- Table: Rural/Urban Breakdown, 2005-2030
- Table: Education, 2000-2005
- Table: Vital Statistics, 2005-2030
- Table: Employment Indicators, 2001-2006
- Table: Consumer Expenditure, 2000-2010 (US$)
- Table: Average Annual Manufacturing Wages, 2000-2012 (IDR)
- Table: Pharmaceutical Business Environment Indicators
- Table: Weighting Of Components